Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China. The company trades on NASDAQ exchange. The company headquarter is located in Guangzhou, China. The company was established in the 2014.

TickerBNR
Long NameBurning Rock Biotech
Short NameBurning Rock Biotech